Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07149363 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
A Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Alliance Foundation Trials.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT07149363: Recruiting Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Alliance Foundation Trials.
NCT07149363 is a Phase 2 study of Small Cell Lung Cancer (SCLC) that is actively recruiting participants, run by Alliance Foundation Trials. The registered enrollment target is 65 participants, below the 289-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07149363, a Phase 2 study of Small Cell Lung Cancer (SCLC), is actively recruiting participants, sponsored by Alliance Foundation Trials.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Primary Outcome
To determine whether the addition of durvalumab to adjuvant chemotherapy after surgery for limited-stage SCLC leads to improved disease free survival (DFS) when compared to historical data of participants who received adjuvant chemotherapy without immunotherapy after surgery for SCLC. DFS is measured in months from the time of surgery.
Conditions Studied
Interventions
- DRUG Durvalumab 50 MG/ML
Study Locations (1)
Virginia
- University of Virginia Comprehensive Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2026-02 |
| Est. Completion | 2031-02 |
| Phase | Phase 2 |
What NCT07149363 shows while recruiting
NCT07149363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 289-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab 50 MG/ML is the first listed.
NCT07149363 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT07149363 about?
NCT07149363 is a clinical study titled "Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer". This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
What is the current status of trial NCT07149363?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2026-02. Estimated completion is 2031-02.
What conditions does trial NCT07149363 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC).
What interventions are being tested in trial NCT07149363?
The interventions under investigation include: Durvalumab 50 MG/ML (DRUG).
Who is sponsoring clinical trial NCT07149363?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07149363 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07149363's enrollment target sits among peer trials
65 10th of 12 higher than 2 of 12 other Small Cell Lung Cancer (SCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Cancer (SCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
RECRUITING · Phase 2
-
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia